Results 71 to 80 of about 1,265,615 (248)

Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”

Toxins, 2014
Targeted immune checkpoint blockade augments anti-tumor immunity and induces durable responses in patients with melanoma and other solid tumors. It also induces specific “immune-related adverse events” (irAEs).
Lucia Gelao, Carmen Criscitiello, Angela Esposito, Aron Goldhirsch, Giuseppe Curigliano   +4 more
doaj   +1 more source

Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review

International Journal of Medical Students, 2020
Programmed cell death protein-1 (PD-1) is an immune checkpoint receptor that induces and maintains tolerance of T cells, invariant natural killer T (iNKT) cells, and natural killer (NK) cells, among other lymphocytes.
Jonathan A. Hermel, Cassi M. Bruni, Darren S. Sigal   +2 more
doaj   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

Predictive biomarkers for tumor immune checkpoint blockade

, 2018
Mengting Tong,1,2,* Jing Wang,2,* Wenting He,1 Yanling Wang,2 Hongming Pan,2 Da Li,2 Hongliang Zhang1 1Second Department of Medical Oncology, The Fourth Affiliated Hospital of Xinjiang Medical University, Saybagh District, Urumqi, Xinjiang 830000, People&
Pan H, Li D, He W, Tong M, Zhang H, Wang Y, Wang J   +6 more
core  

Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents

, 2021
We studied the overview of drug discovery and development to understand the recent trends and potential success factors of interorganizational collaboration by reviewing 1204 transactions performed until 2019 for 107 anticancer drugs approved by the US ...
Arisa Djurian, Tomohiro Makino, Yeongjoo Lim, Shintaro Sengoku, Kota Kodama   +4 more
core   +1 more source

Arginine methylation as a regulatory ratchet in cancer: From substrate selection to malignant‐state stabilization

Molecular Oncology, EarlyView.
Arginine methylation can be viewed as a persistence‐prone post‐translational modification regulated by a network of PRMTs. Competitive and compensatory interactions among PRMTs can redistribute methylation across substrate pools shaped by sequence, structural, spatial, and environmental layers, reinforcing RNA‐processing, chromatin, and signaling ...
So Hyun Kwon, Ji Min Lee
wiley   +1 more source

Bilateral anterior uveitis after immunotherapy for malignant melanoma

Taiwan Journal of Ophthalmology, 2018
Immune checkpoint blockade therapy is relatively a new treatment for cancer which has shown promising results. However, immune-related side effects including uveitis have occasionally been reported during this therapy.
Chia-Jui Chang, Shih-Jen Chen, De-Kuang Hwang, Catherine Jui-Ling Liu   +3 more
doaj   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

ICOS-ImmunoPET Monitors T Cell Activation After Combination Immune Checkpoint Blockade in a Mouse Model of Melanoma Brain Metastasis. [PDF]

Adv Sci (Weinh)
ICOS‐immunoPET noninvasively visualizes activated T cells in melanoma brain metastases following combined anti‐PD‐1/anti‐CTLA‐4 therapy. Clinical translation of this imaging approach may improve patient stratification and treatment monitoring and serve as a quantitative imaging endpoint to support immunotherapy development and clinical trials in brain ...
Kuo RC, Verma R, Nagy SC, Kalita M, Aubert S, Ballesteros-Álvarez J, Almeida PM, Vogel H, Alam IS, Lim M, James ML.   +10 more
europepmc   +2 more sources

Aquaporin‐3 and aquaporin‐5 impact the development of pancreatic ductal adenocarcinoma spheroids

FEBS Open Bio, EarlyView.
Schematic representation of the role of aquaporin‐3 (AQP3) and aquaporin‐5 (AQP5) in pancreatic ductal adenocarcinoma (PDAC). Both proteins are upregulated in PDAC and are associated with tumor progression and metastatic potential. Silencing AQP3 or AQP5 in PDAC spheroids results in decreased diameter, area, and overall growth, underscoring their key ...
Catarina Pimpão, Diogo M. Engrácia, Graça Soveral, Filipa Mendes   +3 more
wiley   +1 more source